Welcome to our dedicated page for Strata Critical Medical SEC filings (Ticker: SRTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Strata Critical Medical, Inc. (Nasdaq: SRTA) provides access to the company’s regulatory disclosures as it executes its strategy in time-critical logistics and medical services for the U.S. healthcare industry. While no specific filings are listed here, Strata’s public communications reference documents such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which contain detailed financial statements, risk factors and management’s discussion of its organ logistics and medical services platform.
Through SEC filings, readers can review how Strata reports the performance of its air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion services, as well as perfusion staffing and equipment solutions offered under the Trinity Medical Solutions and Keystone Perfusion brands. The company also describes non-GAAP metrics like Adjusted EBITDA, Flight Profit, Flight Margin and various free cash flow measures, with reconciliations to GAAP figures typically presented in these filings or related materials.
Regulatory documents also summarize key corporate events that Strata highlights in its news releases, such as the divestiture of its Passenger business, the rebranding from Blade Air Mobility to Strata Critical Medical, the acquisition of Keystone Perfusion and the move to a single operating and reporting segment. Risk factor sections expand on themes the company mentions in press releases, including competition, reliance on transplant centers and organ procurement organizations, operational risks in organ transport and regulatory changes affecting its activities.
On Stock Titan, SEC filings for SRTA are supplemented with AI-powered summaries that explain complex sections in plain language, highlight important changes across reporting periods and help readers quickly identify disclosures related to organ logistics, medical services, acquisitions and non-GAAP performance measures. Real-time updates from EDGAR, combined with these summaries, make it easier to track how Strata’s regulatory reporting reflects its evolving business model in the U.S. healthcare and transplant ecosystem.
Strata Critical Medical, Inc. director and Co-CEO/CFO William A. Heyburn amended a prior insider filing to correctly classify a June 8, 2026 transaction as a tax-withholding event rather than a sale. On that date, 31,671 shares of Class A common stock at $5.87 per share were withheld by the company to cover tax obligations tied to the vesting of restricted stock units, in a transaction approved under Rule 16b-3. After this withholding, Heyburn directly held 1,548,997 shares of Class A common stock.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported a routine tax-related share disposition. On June 8, 2026, 4,655 shares of Class A common stock were withheld by the company at $5.87 per share to cover tax obligations from vested restricted stock units, leaving 146,608 shares owned directly. This amended Form 4 corrects an earlier filing that had mistakenly classified the event as an open-market sale, clarifying it was a tax-withholding transaction approved under Rule 16b-3.
Strata Critical Medical, Inc. director and Co-CEO Melissa M. Tomkiel reported that 29,730 shares of Class A common stock were withheld by the company at $5.87 per share to cover tax obligations from a restricted stock unit vesting. This Form 4/A corrects a prior filing that had mistakenly used a sale code instead of the proper tax-withholding code, while confirming all other details were unchanged. After this tax withholding, she directly holds 1,892,774 shares.
Strata Critical Medical, Inc. CEO, Logistics Scott M. Wunsch filed an amended insider report to correct how a prior share disposition was coded. On June 8, 2026, 5,550 shares of Class A common stock were withheld by the company at $5.87 per share to cover tax obligations from a restricted stock unit vesting, a non-market transaction approved under Rule 16b-3.
The earlier Form 4 had incorrectly used a sale code; this amendment changes it to the proper tax-withholding code F, with all other information unchanged. After the transaction, Wunsch directly holds 625,574 shares, with an additional 382,987 shares held indirectly through a limited liability company he solely owns.
Strata Critical Medical, Inc. ownership update: a group of affiliated investment entities and an associated individual report collective beneficial ownership. As of June 17, 2026, Northern Right Capital Management, L.P. and related reporting persons disclose an aggregate holding of 4,398,235 shares, representing approximately 5.1% of the 86,526,570 shares outstanding (as of April 27, 2026).
The filing breaks holdings into component positions: Northern Right Capital Management, L.P. (4,398,235 shares), Northern Right Capital (QP), L.P. (1,686,941 shares), and Northern Right Long Only Master Fund (1,664,902 shares). Disclaimers note shared voting/dispositive power through adviser and general partner relationships; certain Managed Accounts hold an additional 1,046,392 shares referenced in the filing.
Strata Critical Medical, Inc. Co-CEO and CFO William A. Heyburn reported a Form 4 transaction involving company Class A common stock. On June 8, 2026, 31,671 shares were surrendered at a price of $5.87 per share. According to the footnote, these shares were withheld by the company to cover tax withholding obligations tied to the vesting of restricted stock units, rather than sold in the open market. After this tax-related share withholding, Heyburn held 1,548,997 shares directly, indicating he retained a substantially larger equity position in the company.
Strata Critical Medical, Inc. Co-CEO and CFO William A. Heyburn reported a Form 4 transaction involving company Class A common stock. On June 8, 2026, 31,671 shares were surrendered at a price of $5.87 per share. According to the footnote, these shares were withheld by the company to cover tax withholding obligations tied to the vesting of restricted stock units, rather than sold in the open market. After this tax-related share withholding, Heyburn held 1,548,997 shares directly, indicating he retained a substantially larger equity position in the company.
Strata Critical Medical, Inc. Chief Accounting Officer Cohen Amir reported an open-market sale of Class A common stock. On June 8, 2026, he sold 4,655 shares at $5.87 per share. After this transaction, he directly holds 146,608 shares of the company’s common stock.
Strata Critical Medical, Inc. Chief Accounting Officer Cohen Amir reported an open-market sale of Class A common stock. On June 8, 2026, he sold 4,655 shares at $5.87 per share. After this transaction, he directly holds 146,608 shares of the company’s common stock.
Strata Critical Medical, Inc. director and Co-CEO Melissa M. Tomkiel reported an open-market sale of 29,730 shares of Class A common stock at $5.87 per share on June 8, 2026. Following this transaction, she directly holds 1,892,774 shares of the company’s Class A common stock.
Strata Critical Medical, Inc. director and Co-CEO Melissa M. Tomkiel reported an open-market sale of 29,730 shares of Class A common stock at $5.87 per share on June 8, 2026. Following this transaction, she directly holds 1,892,774 shares of the company’s Class A common stock.
Strata Critical Medical, Inc. CEO of Logistics Scott M. Wunsch reported an open-market sale of 5,550 shares of Class A common stock at $5.87 per share. After this sale, he holds 625,574 shares directly and 382,987 shares indirectly through a limited liability company of which he is the sole member.
Strata Critical Medical, Inc. CEO of Logistics Scott M. Wunsch reported an open-market sale of 5,550 shares of Class A common stock at $5.87 per share. After this sale, he holds 625,574 shares directly and 382,987 shares indirectly through a limited liability company of which he is the sole member.
Strata Critical Medical, Inc. reported results of its annual stockholder meeting held on May 28, 2026. Stockholders elected Class II directors William A. Heyburn and Andrew Lauck to serve until the 2029 annual meeting. Heyburn received 46,050,902 votes for and 505,421 withheld, while Lauck received 39,525,159 for and 7,031,164 withheld, with 12,687,496 broker non-votes for each.
Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 58,946,832 votes for, 65,815 against, and 231,172 abstentions. In an advisory vote, stockholders approved executive compensation with 38,497,962 votes for, 8,022,682 against, 35,679 abstentions, and 12,687,496 broker non-votes.
Strata Critical Medical, Inc. reported results of its annual stockholder meeting held on May 28, 2026. Stockholders elected Class II directors William A. Heyburn and Andrew Lauck to serve until the 2029 annual meeting. Heyburn received 46,050,902 votes for and 505,421 withheld, while Lauck received 39,525,159 for and 7,031,164 withheld, with 12,687,496 broker non-votes for each.
Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 58,946,832 votes for, 65,815 against, and 231,172 abstentions. In an advisory vote, stockholders approved executive compensation with 38,497,962 votes for, 8,022,682 against, 35,679 abstentions, and 12,687,496 broker non-votes.